Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arketamine for Depression With Acute Suicidal Ideation or Behavior (Ib/II)
CTR20241004Phase 2Completed
- Sponsor
- Jiangsu Nhwa Pharmaceutical
- Start
- Mar 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD), suicidal ideation and Suicidality comparing Arketamine arm with Placebo arm (2 arms). Started Mar 2024; status: completed.
02
Drugs
r-ketamine
03
Conditions
major depressive disorder (MDD)suicidal ideationSuicidality
Beyond the preview
Go deeper on CTR20241004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241004.